Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population

Japanese Journal of Clinical Oncology

Volumn 37, Issue 5, 2007, Pages 385-390

  Zhu, Zhong Zheng ^a   Wang, Ai Zhong ^a   Jia, Hang Ruo ^a   Jin, Xia Xiang ^a   He, Xiang Lei ^b   Hou, Li Fang ^c   Zhu, Guanshan ^d  

^a No 113 Hospital of People's Liberation Army   (China)

^b Lihuili Hospital   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Shanghai GeneCore Biotechnologies Co Ltd   (China)

Author keywords

Colorectal cancer; Single nucleotide polymorphism; TP53

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CANCER GRADING; CANCER RISK; CARCINOGENESIS; CHINESE; CIGARETTE SMOKING; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CODON; COLORECTAL NEOPLASMS; GENES, P53; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 34547868921     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym034     Document Type: Article

References (40)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005;11:1809-14.
3. Rupnarain C, Dlamini Z, Naicker S, Bhoola K. Colon cancer: Genomics and apoptotic events. Biol Chem 2004;385:449-64.
4. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002;137:603-12.
5. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: Twenty five years understanding the mechanism of genome protection. J Physiol Biochem 2004;60:287-307.
6. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003;21:271-6.
7. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
8. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353-6.
9. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-60.
10. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Jr., et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 1998;58:1149-58.
11. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7:1343-9.
12. Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 2002;97:451-7.
13. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
14. Irarrazabal CE, Rojas C, Aracena R, Marquez C, Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 2003; 144:69-76.
15. Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000;89:458-64.
16. Hiyama T, Tanaka S, Kitadai Y, Ito M, Sumii M, Yoshihara M, et al. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002;100:304-8.
17. Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 2005;229:77-83.
18. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-6.
19. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 2002;112:116-9.
20. Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 2003;189:77-83.
21. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003;10: 430-5.
22. Chen YC, Xu L, Guo,YL, Su HJ, Hsueh YM, Smith TJ, et al. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003;38:201-11.
23. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996;17:261-4.
24. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181:81-5.
25. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16:1461-4.
26. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001;109:25-34.
27. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, et al. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004;6:529-35.
28. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-9.
29. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23:1954-6.
30. Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12:1426-9.
31. Beckman G, Birgander R, Sjalander A, Saba N, Holmberg PA, Kivela A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
32. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 2003;193:199-205.
33. Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000;60:6875-7.
34. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004;164:1233-41.
35. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, et al. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000;60:2753-5.
36. Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer 2005;92:30-5.
37. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7:149-56.
38. Cai L, Mu LN, Lu H, Lu QY, You NC, Yu SZ, et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:294-300.
39. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-9.
40. Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder HH, et al. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer 2005;114:58-73.